Impact of DNA methylation on the recurrence risk of stage I non-small cell lung cancer with EGFR mutations.

IF 4.8 2区 医学 Q1 GENETICS & HEREDITY
Yunyi Li, Zhihui Yang, Fang Wu, Qingchun Liang, James G Herman, Malcolm V Brock, Wenliang Liu, Fenglei Yu, Xue He, Chen Chen
{"title":"Impact of DNA methylation on the recurrence risk of stage I non-small cell lung cancer with EGFR mutations.","authors":"Yunyi Li, Zhihui Yang, Fang Wu, Qingchun Liang, James G Herman, Malcolm V Brock, Wenliang Liu, Fenglei Yu, Xue He, Chen Chen","doi":"10.1186/s13148-025-01899-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent studies have demonstrated that patients with stage IB-IIIA non-small cell lung cancer (NSCLC) harboring EGFR mutations (EGFRm) can significantly benefit from adjuvant therapy with EGFR-TKIs. Nevertheless, there remains controversial in clinical practice about the use of EGFR-TKI adjuvant therapy for patients with stage IB EGFRm NSCLC.</p><p><strong>Methods: </strong>This retrospective cohort study was conducted at the Second Xiangya Hospital of Central South University. From January 2011 to December 2020, completely resected stage IA-IB NSCLC (8th TNM staging) patients with sensitive EGFR mutation were included. FFPE tumor and lymph node specimens were collected and subjected to the 8-gene methylation panel using modified MOB-qMSP approach. We employed stepwise regression to select variables and logistic regression to establish the predictive model. Cross-validation and decision curve analysis were performed.</p><p><strong>Results: </strong>A total of 242 patients with IA2-IB EGFRm NSCLC were included in the study. Among these patients, 86 constituted the recurrence (Rec) group, while 156 formed the non-recurrence (Non-Rec) group. Through stepwise logistic regression, seven crucial feature variables were identified, including five-gene methylation variables (CDO1, TAC1, p16, CDH13, and APC) and two clinical variables (tumor invasion and differentiation). The ROC analysis revealed an AUC of 0.873 for the model with these seven variables. Internal cross-validation demonstrated a model accuracy exceeding 77%. The nomogram and decision curve analysis underscored the clinical utility of the model. We calculated the total score for each patient based on the nomogram and divided the patients into high-risk and low-risk groups. The cumulative risk curves for both groups evidenced that the recurrence risk in the high-risk group was significantly higher than in the low-risk group. We further divided the dataset into two cohorts-stage IA2-IA3 patients and stage IB patients. The model maintained a high AUC value (0.879) in stage IA2-A3 patients.</p><p><strong>Conclusions: </strong>Our study demonstrates that the methylation of five genes-CDO1, TAC1, p16, CDH13, and APC-in N2 lymph nodes represents a strong biomarker panel for predicting recurrence in stage IB EGFRm NSCLC after curative resection. This approach also shows exceptional predictive accuracy for postoperative recurrence in stage IA2-IA3 EGFRm NSCLC.</p>","PeriodicalId":10366,"journal":{"name":"Clinical Epigenetics","volume":"17 1","pages":"90"},"PeriodicalIF":4.8000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12131548/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epigenetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13148-025-01899-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Recent studies have demonstrated that patients with stage IB-IIIA non-small cell lung cancer (NSCLC) harboring EGFR mutations (EGFRm) can significantly benefit from adjuvant therapy with EGFR-TKIs. Nevertheless, there remains controversial in clinical practice about the use of EGFR-TKI adjuvant therapy for patients with stage IB EGFRm NSCLC.

Methods: This retrospective cohort study was conducted at the Second Xiangya Hospital of Central South University. From January 2011 to December 2020, completely resected stage IA-IB NSCLC (8th TNM staging) patients with sensitive EGFR mutation were included. FFPE tumor and lymph node specimens were collected and subjected to the 8-gene methylation panel using modified MOB-qMSP approach. We employed stepwise regression to select variables and logistic regression to establish the predictive model. Cross-validation and decision curve analysis were performed.

Results: A total of 242 patients with IA2-IB EGFRm NSCLC were included in the study. Among these patients, 86 constituted the recurrence (Rec) group, while 156 formed the non-recurrence (Non-Rec) group. Through stepwise logistic regression, seven crucial feature variables were identified, including five-gene methylation variables (CDO1, TAC1, p16, CDH13, and APC) and two clinical variables (tumor invasion and differentiation). The ROC analysis revealed an AUC of 0.873 for the model with these seven variables. Internal cross-validation demonstrated a model accuracy exceeding 77%. The nomogram and decision curve analysis underscored the clinical utility of the model. We calculated the total score for each patient based on the nomogram and divided the patients into high-risk and low-risk groups. The cumulative risk curves for both groups evidenced that the recurrence risk in the high-risk group was significantly higher than in the low-risk group. We further divided the dataset into two cohorts-stage IA2-IA3 patients and stage IB patients. The model maintained a high AUC value (0.879) in stage IA2-A3 patients.

Conclusions: Our study demonstrates that the methylation of five genes-CDO1, TAC1, p16, CDH13, and APC-in N2 lymph nodes represents a strong biomarker panel for predicting recurrence in stage IB EGFRm NSCLC after curative resection. This approach also shows exceptional predictive accuracy for postoperative recurrence in stage IA2-IA3 EGFRm NSCLC.

DNA甲基化对伴有EGFR突变的I期非小细胞肺癌复发风险的影响
背景:最近的研究表明,携带EGFR突变(EGFRm)的IB-IIIA期非小细胞肺癌(NSCLC)患者可以从EGFR- tkis辅助治疗中显著获益。然而,在临床实践中,EGFR-TKI辅助治疗IB期EGFRm NSCLC患者仍存在争议。方法:在中南大学湘雅二医院进行回顾性队列研究。2011年1月至2020年12月,纳入了EGFR敏感突变的完全切除的IA-IB期NSCLC(第8 TNM分期)患者。收集FFPE肿瘤和淋巴结标本,采用改良的moba - qmsp方法进行8基因甲基化检测。采用逐步回归选择变量,logistic回归建立预测模型。进行交叉验证和决策曲线分析。结果:共有242例IA2-IB EGFRm NSCLC患者纳入研究。其中86例为复发组,156例为非复发组。通过逐步logistic回归,确定了7个关键特征变量,包括5个基因甲基化变量(CDO1、TAC1、p16、CDH13和APC)和2个临床变量(肿瘤侵袭和分化)。ROC分析显示,包含这七个变量的模型AUC为0.873。内部交叉验证表明模型准确率超过77%。nomogram和decision curve分析强调了该模型的临床实用性。我们根据nomogram计算每位患者的总分,并将患者分为高危组和低危组。两组的累积风险曲线显示,高危组的复发风险明显高于低危组。我们进一步将数据集分为两个队列:IA2-IA3期患者和IB期患者。该模型在IA2-A3期患者保持较高的AUC值(0.879)。结论:我们的研究表明,N2淋巴结中5个基因(cdo1、TAC1、p16、CDH13和apc)的甲基化是预测IB期EGFRm非小细胞肺癌根治性切除后复发的一个强有力的生物标志物。该方法对IA2-IA3期EGFRm非小细胞肺癌术后复发的预测也具有卓越的准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
5.30%
发文量
150
期刊介绍: Clinical Epigenetics, the official journal of the Clinical Epigenetics Society, is an open access, peer-reviewed journal that encompasses all aspects of epigenetic principles and mechanisms in relation to human disease, diagnosis and therapy. Clinical trials and research in disease model organisms are particularly welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信